|
body-eff-005
| Switch on XCOPRI sooner |
 |
| #1 branded ASM |
| prescribed by epileptologists* |
 |
| Over 275,000 patients |
| prescribed worldwide and counting† |
 |
| Copay comparable to generics‡ |
| 9 out of 10 Commercial, Medicare, and Medicaid patients have coverage for XCOPRI§ |
 |
| 10+ years of clinical trial and real-world experience |
| Well-studied safety with 5-year retention data1,2 |
|
| #1 branded ASM |
| prescribed by epileptologists* |
|
|
|
| Over 275,000 patients prescribed worldwide and counting† |
|
|
|
| Copay comparable to generics‡ |
| 9 out of 10 Commercial, Medicare, and Medicaid patients have coverage for XCOPRI§ |
|
|
|
| 10+ years of clinical trial and real-world experience |
| Well-studied safety with 5-year retention data1,2 |
|
|
|
| * |
By NBRx, as of July 2025. |
| † |
Worldwide new-to-brand cenobamate prescriptions as of December 2025. Source: IQVIA. |
| ‡ |
IQVIA, Patient Cost Disclosure 12 months ending April 2025. |
| § |
Managed Markets Insight & Technology, LLC, database as of July 2025. |
|
|
|
|
body-saf-001
10+ years of clinical trial and real-world
experience |
| Over 275,000 patients prescribed worldwide* |
|
| * |
Worldwide new-to-brand cenobamate prescriptions as of December 2025. Source: IQVIA. |
|
|
|
|
|
body-tol-001
| Over 275,000 |
| patients prescribed worldwide and counting* |
| * |
Worldwide new-to-brand cenobamate prescriptions as of December 2025. Source: IQVIA. |
|
|
|
|